RECOMBINANT CNTF FOR TREATMENT OF NEUROPATHIES

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16251
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1991
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
California Biotechnology, Inc
2450 Bayshore Parkway, Mountain View, CA, 94043
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Barbara Cordell
 Principal Investigator
 (415) 966-1550
Business Contact
 1 R43 AG09705-01
Phone: () -
Research Institution
N/A
Abstract
CILIARY NEUROTROPHIC FACTOR (CNTF) IS A POTENT POLYPEPTIDE HORMONE WHOSE ACTIONS APPEAR TO BE RESTRICTED TO THE NERVOUS SYSTEM. CNTF HAS BEEN OBSERVED TO PROMOTE SURVIVAL, NEUROTRANSMITTER SYNTHESIS AND NEURITE OUTGROWTH IN VARIOUS SYMPATHETIC, SENSORY AND PARASYMPA- THETIC NEURONS AT FEMTOMOLAR TO LOW PICOMOLAR CONCENTRATIONS. THUS CNTF HAS POTENTIAL CLINICAL APPLICATIONS IN THE TREATMENT OF A NUMBER OF DIFFERENT NEUROPATHIES AND NEURODEGENERATIVE DISORDERS IN MAN AS WELL AS IN THE TREATMENT OF TRAUMATIC NERVE INJURY. IT IS THE GOAL OF THIS PROJECT TO ASSESS THIS POTENTIAL BY FIRST PROVIDING A SOURCE OF HUMAN CNTF USING RECOMBINANT DNA METHODS (PHASE I) AND THEN USING THIS SOURCE TO ESTABLISH EFFICACY IN SPECIFIC ACUTE ANIMAL MODELS OF PERIPHERAL NEUROPATHIES (PHASE II) AND, IF INDICATED, IN HUMAN CLINICAL TRIALS (PHASE III).

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government